



DT02 Rec'd PCT/PTO 11 MAR 2005

#6

Docket No.: 22263-00001-US2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Carlos Martinez-Alonzo et al.

Application No.: 10/500,558

Confirmation No.: 7728

Filed: June 30, 2004

Art Unit: N/A

For: FUNCTIONAL INACTIVATION OF
CXCR4-MEDIATED RESPONSES IN
GROWTH HORMONE TRANSGENIC MICE
THROUGH SOCS3 UP-REGULATION

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached.

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0185, under Order No. 22263-00001-US2. A duplicate copy of this paper is enclosed.

Dated: March 11, 2005

Respectfully submitted,

By 

John A. Evans

Registration No.: 44,100
CONNOLLY BOVE LODGE & HUTZ LLP
1990 M Street, N.W., Suite 800
Washington, DC 20036-3425
(202) 331-7111
(202) 293-6229 (Fax)
Attorney for Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/500,558-Conf. #7728
				Filing Date	June 30, 2004
				First Named Inventor	Carlos Martinez-Alonzo
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	22263-00001-US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

²EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 1998 (1998-03) LEISSNER P ET AL: "In vitro and in vivo inhibition of HIV-1 replication by retroviral transfer of TAT-inducible interferon alpha, beta or gamma genes: Application to gene therapy for AIDS" Database accession no/ PREV199800302718 XP002259515 abstract & ANNALES DE BIOLOGIE CLINIQUE, vol. 56, no. 2, March 1998 (1998-03), pages 167-173, ISSN: 0003-3898.	
	CB	CALIGIURI M A ET AL: "Selective modulation of human natural killer cells in vivo after prolonge infusion of low dose recombinant interleukin 2" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 19, 17 September 1996 (1996-09-17), pages 10405-10410, XP002155131 ISSN: 0027-8424 abstract.	
	CC	JACOBSON E L ET AL: "Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity." PROC. NATL. ACAD. SCI, USA, Vol. 93, pp. 10405-10410, September 1996, Medical Sciences.	
	CD	SORIANO SILVIA F ET AL: "Functional inactivation of CXC chemokine receptor 4-mediated responses through SOCS3 up-regulation." THE JOURNAL OF EXPERIMENTAL MEDICINE. UNITED STATES 5 AUG 2002, vol. 196, no. 3, 5 August 2002 (2002-08-05), pages 311-321, XP002259351 ISSN: 0022-1007 the whole document.	
	CE	VILA-CORO A J ET AL: "The chemokine SDF-1 'alpha' triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway" FASEB JOURNAL 1999 UNITED STATES, vol. 13, no. 13, 1999, pages 1699-1710, XP002259352 ISSN: 0892-6638 cited in the application abstract.	
	CF	AUERNHAMMER C J ET AL: "The central role of SOCS-3 in integrating the neuro-immunoendocrine interface" JOURNAL OF CLINICAL INVESTIGATION 2001 UNITED STATES, vol. 108, no. 12, 2001, pages 1735-1740, XP002259353 ISSN: 0021-9738 the whole document.	
	CG	HESELGESSER J ET AL: "Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 JAN 1998, vol. 160, no. 2, 15 January 1998 (1998-01-15), pages 877-883, XP002259354 ISSN: 0022-1767 abstract.	
Examiner Signature			Date Considered



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/500,558-Conf. #7728
				Filing Date	June 30, 2004
				First Named Inventor	Carlos Martinez-Alonzo
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	22263-00001-US2

CH	KREBS DANIELLE L ET AL: "SOCS proteins: Negative regulators of cytokine signaling" STEM CELLS (MIAMISBURG). vol. 19, no. 5, 2001, pages 378-387, XP002259355 ISSN: 1066-5099 the whole document.	
----	--	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--